Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Indusatumab vedotin

Next Previous
Search
Drug Profile

Indusatumab vedotin

Alternative Names: GCC antibody drug conjugate; MLN-0264; TAK-264

Latest Information Update: 15 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium
  • Developer Takeda Oncology
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Enterotoxin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Gastrointestinal cancer; Pancreatic cancer

Most Recent Events

  • 14 Dec 2023 Seagen has been acquired by Pfizer
  • 08 Oct 2020 Seattle Genetics is now called Seagen
  • 06 Apr 2017 Millennium Pharmaceuticals terminated a phase II trial due to a business decision in Pancreatic cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA, Italy, Belgium, Spain and United Kingdom (IV) (NCT02202785)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top